American Association for Cancer Research
crc-23-0249-s07.pptx (4.84 MB)

Figure S7 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Anti-Tumor Activity Against Prostaglandin-Expressing Tumors

Download (4.84 MB)
posted on 2023-07-13, 13:20 authored by Brian J. Francica, Anja Holtz, Justine M Lopez, David Freund, Austin Chen, Dingzhi Wang, David Powell, Franciele C Kipper, Dipak Panigrahy, Raymond N DuBois, Chan C. Whiting, Peppi Prasit, Thomas W Dubensky

Histopathological analysis of resected APCmin/+ colon hyperplasia



While the role of prostaglandin E2 (PGE2) in promoting malignant progression is well-established, how to optimally block the activity of PGE2 signaling remains to be demonstrated. Clinical trials with prostaglandin pathway targeted agents have shown activity but without sufficient significance or dose-limiting toxicities that have prevented approval. PGE2 signals through four receptors (EP1-4) to modulate tumor progression. EP2 and EP4 signaling exacerbates tumor pathology and is immunosuppressive through potentiating cAMP production. EP1 and EP3 signaling has the opposite effect through increasing IP3 and decreasing cAMP. Using available single small molecule antagonists of EP receptors, the COX-2 inhibitor celecoxib and a dual EP2/EP4 antagonist generated in this investigation, we tested which approach to block PGE2 signaling optimally restored immunologic activity in mouse and human immune cells and antitumor activity in syngeneic, spontaneous and xenograft tumor models. We found that dual antagonism of EP2 and EP4 together significantly enhanced the activation of PGE2-suppressed mouse and human monocytes and CD8+ T cells in vitro as compared to single EP antagonists. CD8+ T cell activation was dampened by single EP1 and EP3 antagonists. Dual EP2/EP4 PGE2 receptor antagonists increased TME lymphocyte infiltration and significantly reduced disease burden in multiple tumor models, including in the adenomatous polyposis coli (APC)min+/- spontaneous colorectal tumor model, compared to celecoxib. These results support a hypothesis that redundancy of EP2 and EP4 receptor signaling necessitates a therapeutic strategy of dual blockade of EP2 and EP4. Here we describe TPST-1495, a first-in-class orally available small molecule dual EP2/EP4 antagonist.